Cargando…
The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics
Lewy body diseases (LBD) are pathologically defined as the accumulation of Lewy bodies composed of an aggregation of α-synuclein (αSyn). In LBD, not only the sole aggregation of αSyn but also the co-aggregation of amyloidogenic proteins, such as amyloid-β (Aβ) and tau, has been reported. In this rev...
Autores principales: | Noguchi-Shinohara, Moeko, Ono, Kenjiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298861/ https://www.ncbi.nlm.nih.gov/pubmed/37373401 http://dx.doi.org/10.3390/ijms241210215 |
Ejemplares similares
-
Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia
por: Miller, Rebecca L., et al.
Publicado: (2022) -
The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders
por: Irwin, David J., et al.
Publicado: (2018) -
Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and α-synuclein pathologies in the hippocampus of patients with Alzheimer’s disease and dementia with Lewy bodies
por: Fixemer, Sonja, et al.
Publicado: (2022) -
Evaluating the relationship between
amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies
and Parkinson’s disease
por: Swirski, Marta, et al.
Publicado: (2014) -
The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
por: Abdelnour, Carla, et al.
Publicado: (2020)